Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials.

MLA

Strand, Vibeke, et al. “Immunogenicity of Adalimumab Reference Product and Adalimumab-Adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE Trials.” BMJ Open, vol. 14, no. 11, Nov. 2024, p. e081687. EBSCOhost, https://doi.org/10.1136/bmjopen-2023-081687.

APA

Strand, V., McCabe, D., & Bender, S. (2024). Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn’s disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials. BMJ Open, 14(11), e081687. https://doi.org/10.1136/bmjopen-2023-081687

Chicago

Strand, Vibeke, Dorothy McCabe, and Shaun Bender. 2024. “Immunogenicity of Adalimumab Reference Product and Adalimumab-Adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE Trials.” BMJ Open 14 (11): e081687. doi:10.1136/bmjopen-2023-081687.